Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma

Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma

More than 50% of human cancers harbor <i>TP53</i> mutations and increased expression of <i>Mouse double minute 2 homolog</i> <i>(MDM2)</i>, which contribute to cancer progression and drug resistance. Renal cell carcinoma (RCC) has an unusually high incidence of wi...

Full description

Bibliographic Details
Main Authors: Joon Hee Kang, Seon-Hyeong Lee, Jae-Seon Lee, Su-Jin Oh, Ji Sun Ha, Hyun-Jung Choi, Soo-Youl Kim
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cells
Subjects:
MDM2
p53
transglutaminase 2
nutlin-3a
Online Access:https://www.mdpi.com/2073-4409/9/6/1475

Internet

https://www.mdpi.com/2073-4409/9/6/1475

Similar Items